|
DE3382562D1
(de)
|
1982-09-24 |
1992-06-25 |
Us Health |
Wiederherstellung von gewebe bei tieren.
|
|
JPH0637520B2
(ja)
|
1985-07-03 |
1994-05-18 |
味の素株式会社 |
ポリペプチド
|
|
EP0272253A4
(en)
|
1986-03-07 |
1990-02-05 |
Massachusetts Inst Technology |
METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
|
|
US4973577A
(en)
|
1986-04-04 |
1990-11-27 |
The Salk Institute For Biological Studies |
FSH-releasing peptides
|
|
WO1992004913A1
(en)
|
1990-09-13 |
1992-04-02 |
Children's Hospital Medical Center Of Northern California |
Method for increasing red blood cell production by treatment with activin or activin-related peptides
|
|
US5118667A
(en)
|
1991-05-03 |
1992-06-02 |
Celtrix Pharmaceuticals, Inc. |
Bone growth factors and inhibitors of bone resorption for promoting bone formation
|
|
WO1992020793A1
(en)
|
1991-05-10 |
1992-11-26 |
The Salk Institute For Biological Studies |
CLONING AND RECOMBINANT PRODUCTION OF RECEPTOR(S) OF THE ACTIVIN/TGF-β SUPERFAMILY
|
|
US5885794A
(en)
|
1991-05-10 |
1999-03-23 |
The Salk Institute For Biological Studies |
Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
|
|
US6162896A
(en)
*
|
1991-05-10 |
2000-12-19 |
The Salk Institute For Biological Studies |
Recombinant vertebrate activin receptors
|
|
US20050186593A1
(en)
|
1991-05-10 |
2005-08-25 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
|
US6287816B1
(en)
|
1991-06-25 |
2001-09-11 |
Genetics Institute, Inc. |
BMP-9 compositions
|
|
US5661007A
(en)
|
1991-06-25 |
1997-08-26 |
Genetics Institute, Inc. |
Bone morphogenetic protein-9 compositions
|
|
US6692925B1
(en)
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
|
EP1475440A3
(en)
|
1993-01-12 |
2004-11-17 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor-3
|
|
DE69433742T2
(de)
|
1993-05-12 |
2005-07-07 |
Genetics Institute, LLC, Cambridge |
Bmp-10 zusammensetzungen
|
|
US5637480A
(en)
|
1993-05-12 |
1997-06-10 |
Genetics Institute, Inc. |
DNA molecules encoding bone morphogenetic protein-10
|
|
US5831050A
(en)
|
1993-06-07 |
1998-11-03 |
Creative Biomolecules, Inc. |
Morphogen cell surface receptor
|
|
EP0726948B1
(en)
|
1993-10-14 |
2007-02-28 |
President And Fellows Of Harvard College |
Method of inducing and maintaining neuronal cells
|
|
US5658876A
(en)
|
1994-04-28 |
1997-08-19 |
The General Hospital Corporation |
Activin antagonists as novel contraceptives
|
|
CA2194660C
(en)
|
1994-07-08 |
2009-09-29 |
Se-Jin Lee |
Growth differentiation factor-11
|
|
US5760010A
(en)
|
1995-01-01 |
1998-06-02 |
Klein; Ira |
Method of treating liver disorders with a macrolide antibiotic
|
|
US6132988A
(en)
|
1995-10-27 |
2000-10-17 |
Takeda Chemical Industries, Ltd. |
DNA encoding a neuronal cell-specific receptor protein
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
US6004780A
(en)
*
|
1996-03-26 |
1999-12-21 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
|
US20050244867A1
(en)
*
|
1996-03-26 |
2005-11-03 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
|
EP0939816A1
(en)
|
1996-10-25 |
1999-09-08 |
G.D. SEARLE & CO. |
Circularly permuted erythropoietin receptor agonists
|
|
US6605699B1
(en)
|
1997-01-21 |
2003-08-12 |
Human Genome Sciences, Inc. |
Galectin-11 polypeptides
|
|
US6034062A
(en)
|
1997-03-13 |
2000-03-07 |
Genetics Institute, Inc. |
Bone morphogenetic protein (BMP)-9 compositions and their uses
|
|
US7041641B2
(en)
|
1997-03-20 |
2006-05-09 |
Stryker Corporation |
Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
|
|
US6426411B1
(en)
|
1997-05-30 |
2002-07-30 |
Dana-Farber Cancer Institute |
PGC-1, a novel brown fat pparγ coactivator
|
|
US6231880B1
(en)
|
1997-05-30 |
2001-05-15 |
Susan P. Perrine |
Compositions and administration of compositions for the treatment of blood disorders
|
|
US6696260B1
(en)
|
1997-08-01 |
2004-02-24 |
The Johns Hopkins University School Of Medicine |
Methods to identify growth differentiation factor (GDF) binding proteins
|
|
AU8666398A
(en)
|
1997-08-01 |
1999-02-22 |
Johns Hopkins University School Of Medicine, The |
Methods to identify growth differentiation factor (gdf) receptors
|
|
US6656475B1
(en)
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
|
EP1015468A4
(en)
|
1997-08-29 |
2000-09-06 |
Human Genome Sciences Inc |
FOLLISTATINE-3
|
|
US6953662B2
(en)
|
1997-08-29 |
2005-10-11 |
Human Genome Sciences, Inc. |
Follistatin-3
|
|
JP3992298B2
(ja)
|
1997-10-03 |
2007-10-17 |
中外製薬株式会社 |
天然ヒト型化抗体
|
|
US6696411B1
(en)
*
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
|
EP1113799A4
(en)
|
1998-09-17 |
2004-06-09 |
Lilly Co Eli |
PROTEIN-BASED PREPARATION
|
|
CA2343715C
(en)
*
|
1998-09-22 |
2004-05-18 |
Long Yu |
New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
|
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
|
US6238860B1
(en)
|
1998-11-05 |
2001-05-29 |
Dyax Corp. |
Binding moieties for human parvovirus B19
|
|
US6777205B1
(en)
*
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
|
BR0008188A
(pt)
|
1999-01-21 |
2002-02-13 |
Metamorphix Inc |
Inibidores de fator de diferenciação de crescimento e usos para os mesmos
|
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
|
AU777783B2
(en)
|
1999-04-19 |
2004-10-28 |
Kyowa Hakko Kogyo Co. Ltd. |
Proliferation inhibitor for androgen-independent tumor
|
|
US6468543B1
(en)
|
1999-05-03 |
2002-10-22 |
Zymogenetics, Inc. |
Methods for promoting growth of bone using ZVEGF4
|
|
HRP20020387A2
(en)
|
1999-11-12 |
2005-10-31 |
Maxygen Holdings Ltd. |
Interferon gamma conjugates
|
|
WO2001043763A1
(en)
|
1999-12-15 |
2001-06-21 |
Research Development Foundation |
Betaglycan as an inhibin receptor and uses thereof
|
|
US20030224501A1
(en)
|
2000-03-17 |
2003-12-04 |
Young Paul E. |
Bone morphogenic protein polynucleotides, polypeptides, and antibodies
|
|
JP4487376B2
(ja)
|
2000-03-31 |
2010-06-23 |
味の素株式会社 |
腎疾患治療剤
|
|
CZ304855B6
(cs)
|
2000-05-15 |
2014-12-10 |
F. Hoffmann-La Roche Ag |
Kapalná farmaceutická kompozice obsahující pegylovaný lidský erythropoetin, způsob její přípravy, léčivo pro léčení chorob korelujících s anemií při chronickém renálním selhání a zařízení s jejím obsahem
|
|
US6627424B1
(en)
|
2000-05-26 |
2003-09-30 |
Mj Bioworks, Inc. |
Nucleic acid modifying enzymes
|
|
AU2001269709A1
(en)
|
2000-07-19 |
2002-02-05 |
Eli Lilly And Company |
Nucleic acids, vectors, host cells, polypeptides, and uses thereof
|
|
US6632180B1
(en)
|
2000-09-07 |
2003-10-14 |
John H. Laragh |
Method for evaluating and treating hypertension
|
|
DE10045591A1
(de)
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
|
US7087224B2
(en)
*
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
|
AU2002225670B2
(en)
|
2000-11-20 |
2006-05-11 |
The Board Of Trustees Of The University Of Illinois |
Membrane scaffold proteins
|
|
EP1370287A2
(en)
|
2000-12-01 |
2003-12-17 |
Wyeth |
Method and composition for modulating bone growth
|
|
US20030082233A1
(en)
|
2000-12-01 |
2003-05-01 |
Lyons Karen M. |
Method and composition for modulating bone growth
|
|
TW200526779A
(en)
|
2001-02-08 |
2005-08-16 |
Wyeth Corp |
Modified and stabilized GDF propeptides and uses thereof
|
|
US20040132675A1
(en)
*
|
2002-02-08 |
2004-07-08 |
Calvin Kuo |
Method for treating cancer and increasing hematocrit levels
|
|
US7294472B2
(en)
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
|
US20040121008A1
(en)
|
2001-03-16 |
2004-06-24 |
Keiko Shiraishi |
Process for producing sustained release preparation
|
|
DK1436003T3
(da)
|
2001-05-24 |
2010-03-15 |
Zymogenetics Inc |
TACI-immunoglobulin-fusionsproteiner
|
|
AU2001286171B2
(en)
|
2001-05-25 |
2008-01-10 |
Serono Genetics Institute S.A. |
Human CDNAs and proteins and uses thereof
|
|
AUPR638101A0
(en)
|
2001-07-13 |
2001-08-09 |
Bioa Pty Limited |
Composition and method for treatment of disease
|
|
KR101021817B1
(ko)
|
2001-07-17 |
2011-03-17 |
데이진 가부시키가이샤 |
ＰＰＡＲ δ활성화 작용을 측정하는 것을 특징으로 하는 물질의 선택방법 및 약제
|
|
US6855344B2
(en)
|
2001-07-17 |
2005-02-15 |
Integrated Chinese Medicine Holdings, Ltd. |
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
|
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
US6784154B2
(en)
|
2001-11-01 |
2004-08-31 |
University Of Utah Research Foundation |
Method of use of erythropoietin to treat ischemic acute renal failure
|
|
WO2003053997A2
(en)
|
2001-12-06 |
2003-07-03 |
Fibrogen, Inc. |
Methods of increasing endogenous erythropoietin (epo)
|
|
US20060234918A1
(en)
|
2001-12-19 |
2006-10-19 |
Voyager Pharmaceutical Corporation |
Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
|
|
US20030144203A1
(en)
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
|
US6998118B2
(en)
|
2001-12-21 |
2006-02-14 |
The Salk Institute For Biological Studies |
Targeted retrograde gene delivery for neuronal protection
|
|
WO2003068801A2
(en)
|
2002-02-11 |
2003-08-21 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
|
MXPA04008150A
(es)
|
2002-02-21 |
2005-06-17 |
Wyeth Corp |
Gasp1: una proteina que contiene dominio de folistatina.
|
|
US20030219846A1
(en)
|
2002-02-28 |
2003-11-27 |
Pfizer Inc. |
Assay for activity of the ActRIIB kinase
|
|
US8053552B2
(en)
|
2002-04-18 |
2011-11-08 |
Mtm Laboratories, Ag |
Neopeptides and methods useful for detection and treatment of cancer
|
|
US7632679B2
(en)
|
2002-07-16 |
2009-12-15 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods for screening for modulators of neural differentiation
|
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
|
CA2497304A1
(en)
|
2002-08-16 |
2004-02-26 |
Wyeth |
Bmp-2 estrogen responsive element and methods of using the same
|
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
|
US20040223966A1
(en)
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
|
AU2002953327A0
(en)
|
2002-12-12 |
2003-01-09 |
Monash University |
Methods of diagnosing prognosing and treating activin associated diseases and conditions
|
|
DE04708802T1
(de)
|
2003-02-07 |
2006-06-22 |
Prometic Biosciences Inc., Montreal |
Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
|
|
WO2004086953A2
(en)
|
2003-03-26 |
2004-10-14 |
The Board Of Trustees Of The University Of Arkansas |
Method for diagnosis and treatment of bone turnover
|
|
US20070184052A1
(en)
|
2003-05-09 |
2007-08-09 |
Lin Herbert Y |
Soluble tgf-b type III receptor fusion proteins
|
|
US7785587B2
(en)
|
2003-06-02 |
2010-08-31 |
Wyeth |
Therapeutic methods for muscular or neuromuscular disorders
|
|
NZ544618A
(en)
|
2003-06-16 |
2009-02-28 |
Celltech R & D Inc |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
|
WO2005009460A2
(en)
|
2003-07-25 |
2005-02-03 |
Medexis, S.A. |
Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
|
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
|
EP1706428B1
(en)
|
2004-01-22 |
2009-09-23 |
MERCK PATENT GmbH |
Anti-cancer antibodies with reduced complement fixation
|
|
US20050197292A1
(en)
*
|
2004-01-30 |
2005-09-08 |
Glennda Smithson |
Compositions and methods for treating T-cell mediated pathological conditions
|
|
WO2005094871A2
(en)
|
2004-03-26 |
2005-10-13 |
Acceleron Pharma Inc. |
Bmp-3 propeptides and related methods
|
|
JP2008500816A
(ja)
|
2004-03-31 |
2008-01-17 |
ゼンコー・インコーポレイテッド |
改善された性質を有するｂｍｐ−７変異体
|
|
WO2005113590A2
(en)
|
2004-05-12 |
2005-12-01 |
Acceleron Pharma Inc. |
Bmp10 propeptides and related methods
|
|
EP1771557B1
(en)
|
2004-06-24 |
2014-12-31 |
Acceleron Pharma Inc. |
GDF3 Propeptides and Related Methods
|
|
ES2551852T3
(es)
|
2004-07-23 |
2015-11-24 |
Acceleron Pharma Inc. |
Polipéptidos del receptor ActRII
|
|
EP1794191B1
(en)
|
2004-08-05 |
2016-05-18 |
The Regents of The University of California |
Molecules with effects on cellular development and function
|
|
US20060034831A1
(en)
|
2004-08-12 |
2006-02-16 |
Wyeth |
Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
|
|
EP1804824B1
(en)
|
2004-09-29 |
2017-01-04 |
Icahn School of Medicine at Mount Sinai |
Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
US7968091B2
(en)
|
2005-02-16 |
2011-06-28 |
The General Hospital Corporation |
Methods and compositions to regulate iron metabolism
|
|
JPWO2006115274A1
(ja)
|
2005-04-26 |
2008-12-18 |
味の素株式会社 |
骨髄赤血球前駆細胞分化促進剤
|
|
JP2007099764A
(ja)
|
2005-09-09 |
2007-04-19 |
Ajinomoto Co Inc |
血糖低下剤
|
|
JP2009510093A
(ja)
|
2005-09-28 |
2009-03-12 |
ザイモジェネティクス， インコーポレイテッド |
Ｉｌ−１７ａおよびｉｌ−１７ｆアンタゴニストならびにその使用方法
|
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
|
EA201692543A1
(ru)
|
2005-11-23 |
2017-08-31 |
Акселерон Фарма Инк. |
Антагонисты активина-actriia и их применение для стимулирования роста кости
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
US20070149458A1
(en)
|
2005-12-06 |
2007-06-28 |
Amgen Inc. |
Uses of myostatin antagonists
|
|
WO2007071023A1
(en)
|
2005-12-20 |
2007-06-28 |
Merck Frosst Canada Ltd. |
Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
|
|
WO2007075702A2
(en)
|
2005-12-21 |
2007-07-05 |
Schering Corporation |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
|
|
WO2007076127A2
(en)
|
2005-12-22 |
2007-07-05 |
Biogen Idec Ma Inc |
Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
|
|
US7361510B2
(en)
|
2006-01-20 |
2008-04-22 |
Beckman Coulter, Inc. |
Methods of detection of iron deficiency
|
|
CA2637375A1
(en)
|
2006-01-25 |
2007-08-02 |
Wellstat Therapeutics Corporation |
Compounds for the treatment of metabolic disorders
|
|
CA2642662A1
(en)
|
2006-02-28 |
2007-09-07 |
Wellstat Therapeutics Corporation |
Compounds for the treatment of metabolic disorders
|
|
WO2007120767A2
(en)
*
|
2006-04-14 |
2007-10-25 |
Amgen Inc. |
Agonist erythropoietin receptor antibodies
|
|
WO2007123391A1
(en)
|
2006-04-20 |
2007-11-01 |
Academisch Ziekenhuis Leiden |
Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
|
|
BRPI0713096A2
(pt)
|
2006-05-09 |
2012-10-16 |
Hemaquest Pharmaceuticals Inc |
métodos para tratar distúrbios sangüìneos
|
|
BRPI0714882A2
(pt)
|
2006-07-21 |
2013-05-21 |
Lyne Lab |
composiÇço lÍquida de acetato de cÁlcio e uso de uma soluÇço aquosa que compreende entre cerca de 7% (p/v) e cerca de 21% (p/v) de acetato de cÁlcio
|
|
GB0615129D0
(en)
|
2006-07-29 |
2006-09-06 |
Univ Cardiff |
Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
WO2008060139A1
(en)
|
2006-11-17 |
2008-05-22 |
Erasmus University Medical Center Rotterdam |
Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
|
|
WO2008073292A2
(en)
|
2006-12-08 |
2008-06-19 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
|
|
AU2007332473B2
(en)
|
2006-12-14 |
2012-09-27 |
Forerunner Pharma Research Co., Ltd. |
Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
|
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
EP2468291B1
(en)
|
2006-12-18 |
2017-11-22 |
Acceleron Pharma, Inc. |
Activin-actrii antagonists and uses for increasing red blood cell levels
|
|
CA2677007A1
(en)
|
2007-02-01 |
2008-08-07 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for treating or preventing breast cancer
|
|
TWI782836B
(zh)
|
2007-02-02 |
2022-11-01 |
美商艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
|
CA3039330C
(en)
|
2007-02-09 |
2021-11-09 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for promoting bone growth in cancer patients
|
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
|
TWI573802B
(zh)
|
2007-03-06 |
2017-03-11 |
安美基公司 |
變異之活動素受體多肽及其用途
|
|
US20090017019A1
(en)
|
2007-06-01 |
2009-01-15 |
Wyeth |
Methods and compositions for modulating bmp-10 activity
|
|
WO2009009059A1
(en)
|
2007-07-09 |
2009-01-15 |
Biogen Idec Ma Inc. |
Spiro compounds as antagonists of tgf-beta
|
|
LT2170396T
(lt)
|
2007-08-03 |
2017-03-10 |
Summit (Oxford) Limited |
Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui
|
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
|
GB0715938D0
(en)
|
2007-08-15 |
2007-09-26 |
Vastox Plc |
Method of treatment of duchenne muscular dystrophy
|
|
WO2009025651A1
(en)
|
2007-08-17 |
2009-02-26 |
University Of Maine System Board Of Trustees |
Biologically active peptide and method of using the same
|
|
WO2009035629A1
(en)
|
2007-09-13 |
2009-03-19 |
Ludwig Institute Of Cancer Research |
Method for modifying cellular immune response by modulating activin activity
|
|
CN103877564A
(zh)
|
2007-09-18 |
2014-06-25 |
阿塞勒隆制药公司 |
活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
US8043620B2
(en)
|
2007-11-21 |
2011-10-25 |
Amgen Inc. |
Wise binding agents and epitopes
|
|
EP2265603B1
(en)
|
2008-03-13 |
2014-05-07 |
The General Hospital Corporation |
Inhibitors of the bmp signaling pathway
|
|
JP2011523357A
(ja)
|
2008-05-06 |
2011-08-11 |
ジョスリン ダイアビーティス センター インコーポレイテッド |
褐色脂肪細胞分化を誘導するための方法および組成物
|
|
WO2009137075A1
(en)
|
2008-05-06 |
2009-11-12 |
Acceleron Pharma Inc. |
Anti-activin antibodies and uses for promoting bone growth
|
|
US20100008918A1
(en)
|
2008-06-26 |
2010-01-14 |
Acceleron Pharma Inc. |
Methods for dosing an actriib antagonist and monitoring of treated patients
|
|
NZ590326A
(en)
|
2008-06-26 |
2013-05-31 |
Acceleron Pharma Inc |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
JP5922928B2
(ja)
*
|
2008-08-14 |
2016-05-24 |
アクセルロン ファーマ， インコーポレイテッド |
赤血球レベルを高めるためのｇｄｆトラップの使用
|
|
US20110293526A1
(en)
|
2008-11-20 |
2011-12-01 |
University Of Southern California |
Compositions and methods to modulate hair growth
|
|
ME02652B
(me)
|
2008-11-26 |
2017-06-20 |
Amgen Inc |
Stabilizovana varijanta aktivin iib receptora
|
|
EP2387412A4
(en)
*
|
2009-01-13 |
2013-04-03 |
Acceleron Pharma Inc |
PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
|
|
US8110355B2
(en)
|
2009-02-20 |
2012-02-07 |
GenRemedy, LLC |
Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
|
|
NO2424895T3
(enExample)
|
2009-04-27 |
2018-02-03 |
|
|
|
CN102482339B
(zh)
|
2009-06-08 |
2015-06-17 |
阿塞勒隆制药公司 |
用于增加产热脂肪细胞的方法
|
|
EP2440577A4
(en)
|
2009-06-12 |
2013-01-23 |
Acceleron Pharma Inc |
SHORTEN ACTRIIB FC FUSION PROTEINS
|
|
ES2796121T3
(es)
*
|
2009-08-13 |
2020-11-25 |
Acceleron Pharma Inc |
Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos
|
|
CA2773494A1
(en)
|
2009-09-09 |
2011-03-17 |
Acceleron Pharma Inc. |
Actriib antagonists and dosing and uses thereof
|
|
CA2779472C
(en)
|
2009-11-03 |
2021-03-16 |
Acceleron Pharma Inc. |
The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease
|
|
ES2658292T3
(es)
|
2009-11-17 |
2018-03-09 |
Acceleron Pharma, Inc. |
Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
|
|
US8580922B2
(en)
|
2011-03-04 |
2013-11-12 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
|
PL2726099T3
(pl)
|
2011-07-01 |
2018-12-31 |
Novartis Ag |
Sposób leczenia zaburzeń metabolicznych
|
|
CA2852683A1
(en)
|
2011-10-17 |
2013-04-25 |
Acceleron Pharma, Inc. |
Methods and compositions for treating ineffective erythropoiesis
|
|
US8765385B2
(en)
|
2011-10-27 |
2014-07-01 |
Ravindra Kumar |
Method of detection of neutralizing anti-actriib antibodies
|
|
WO2013063536A1
(en)
|
2011-10-27 |
2013-05-02 |
Acceleron Pharma, Inc. |
Actriib binding agents and uses thereof
|
|
BR112014009949A8
(pt)
|
2011-10-28 |
2018-01-16 |
Paranta Biosciences Ltd |
métodos de tratamento de hipersecreção de muco e uso de agentes
|
|
JP6145112B2
(ja)
|
2011-12-19 |
2017-06-07 |
アムジエン・インコーポレーテツド |
単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
EP3521310A1
(en)
|
2012-06-14 |
2019-08-07 |
The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center |
Use of blocking agents of bone morphogenic protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
|
|
CN104411720B
(zh)
|
2012-07-02 |
2018-05-11 |
协和发酵麒麟株式会社 |
以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂
|
|
CN104968801B
(zh)
|
2012-10-24 |
2021-06-15 |
细胞基因公司 |
用于治疗贫血症的生物标志物
|
|
CN104981250A
(zh)
|
2012-10-24 |
2015-10-14 |
细胞基因公司 |
用于治疗贫血的方法
|
|
WO2014064292A1
(en)
|
2012-10-26 |
2014-05-01 |
Universite Pierre Et Marie Curie (Paris 6) |
A method for preventing or treating atrial fibrillation
|
|
MX366336B
(es)
|
2012-11-02 |
2019-07-05 |
Celgene Corp |
Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
|
|
CA3240136A1
(en)
|
2012-11-08 |
2014-05-15 |
Clearside Biomedical, Inc. |
Methods and devices for the treatment of ocular diseases in human subjects
|
|
WO2014093531A1
(en)
|
2012-12-11 |
2014-06-19 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Modulation of myofiber repair by anti-myostatin in strategies with stem cells
|
|
US20140220033A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an Anti-Activin-A Compound to a Subject
|
|
EP3431592A1
(en)
|
2013-03-14 |
2019-01-23 |
Translate Bio, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
|
TWI655207B
(zh)
|
2013-07-30 |
2019-04-01 |
再生元醫藥公司 |
抗活化素ａ之抗體及其用途
|
|
TW201536318A
(zh)
|
2013-08-14 |
2015-10-01 |
Novartis Ag |
治療偶發性包涵體肌炎之方法
|
|
JP2017505428A
(ja)
|
2013-12-16 |
2017-02-16 |
パランタ バイオサイエンス リミテッド |
診断及び治療の方法
|
|
WO2015108972A1
(en)
|
2014-01-14 |
2015-07-23 |
Santa Maria Biotherapeutics, Inc. |
Activin inhibitor response prediction and uses for treatment
|
|
US20170248609A1
(en)
|
2014-01-27 |
2017-08-31 |
Novartis Ag |
Biomarkers predictive of muscle atrophy, method and use
|
|
JP6601687B2
(ja)
|
2014-03-31 |
2019-11-06 |
大日本住友製薬株式会社 |
進行性骨化性線維異形成症の予防剤及び治療剤
|
|
JP6649895B2
(ja)
|
2014-04-18 |
2020-02-19 |
アクセルロン ファーマ， インコーポレイテッド |
赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
|
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
|
AU2015274293A1
(en)
|
2014-06-13 |
2017-02-02 |
Amgen Inc. |
Formulated receptor polypeptides and related methods
|
|
HK1251157A1
(zh)
|
2015-05-13 |
2019-01-25 |
细胞基因公司 |
使用ACTRII配体陷阱治疗β-地中海贫血
|